154 related articles for article (PubMed ID: 8433467)
1. Prospective study of serum CA-125 levels as markers of ovarian cancer.
Helzlsouer KJ; Bush TL; Alberg AJ; Bass KM; Zacur H; Comstock GW
JAMA; 1993 Mar; 269(9):1123-6. PubMed ID: 8433467
[TBL] [Abstract][Full Text] [Related]
2. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
Jacobs IJ; Oram DH; Bast RC
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.
Einhorn N; Sjövall K; Knapp RC; Hall P; Scully RE; Bast RC; Zurawski VR
Obstet Gynecol; 1992 Jul; 80(1):14-8. PubMed ID: 1603484
[TBL] [Abstract][Full Text] [Related]
4. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
5. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.
Tailor A; Bourne TH; Campbell S; Okokon E; Dew T; Collins WP
Ultrasound Obstet Gynecol; 2003 Apr; 21(4):378-85. PubMed ID: 12704748
[TBL] [Abstract][Full Text] [Related]
6. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
[TBL] [Abstract][Full Text] [Related]
7. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer.
Zurawski VR; Broderick SF; Pickens P; Knapp RC; Bast RC
Obstet Gynecol; 1987 Apr; 69(4):606-11. PubMed ID: 2434895
[TBL] [Abstract][Full Text] [Related]
8. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
9. CA 125 as a screening test for ovarian cancer.
Hakama M; Stenman UH; Knekt P; Järvisalo J; Hakulinen T; Maatela J; Aromaa A
J Med Screen; 1996; 3(1):40-2. PubMed ID: 8861050
[TBL] [Abstract][Full Text] [Related]
10. [Studies of clinical usefulness of new tumor markers of ovarian cancer, CA 54/61 and CA 602--CA 602 assay reagent kit, performance its normal value and correlations with other tumor markers].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2085-93. PubMed ID: 1417016
[TBL] [Abstract][Full Text] [Related]
11. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer.
Bourne TH; Campbell S; Reynolds K; Hampson J; Bhatt L; Crayford TJ; Whitehead MI; Collins WP
Gynecol Oncol; 1994 Mar; 52(3):379-85. PubMed ID: 8157195
[TBL] [Abstract][Full Text] [Related]
12. Serum gonadotropins and steroid hormones and the development of ovarian cancer.
Helzlsouer KJ; Alberg AJ; Gordon GB; Longcope C; Bush TL; Hoffman SC; Comstock GW
JAMA; 1995 Dec; 274(24):1926-30. PubMed ID: 8568986
[TBL] [Abstract][Full Text] [Related]
13. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].
Yang ZJ; Yang G; Jiang YM; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
Zhonghua Fu Chan Ke Za Zhi; 2011 Feb; 46(2):113-8. PubMed ID: 21426769
[TBL] [Abstract][Full Text] [Related]
15. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis.
Whitmore SE; Anhalt GJ; Provost TT; Zacur HA; Hamper UM; Helzlsouer KJ; Rosenshein NB
Gynecol Oncol; 1997 May; 65(2):241-4. PubMed ID: 9159332
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer.
Zurawski VR; Orjaseter H; Andersen A; Jellum E
Int J Cancer; 1988 Nov; 42(5):677-80. PubMed ID: 3182103
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing serum CA 125 levels in normal women.
Grover S; Quinn MA; Weideman P; Koh H
Obstet Gynecol; 1992 Apr; 79(4):511-4. PubMed ID: 1553167
[TBL] [Abstract][Full Text] [Related]
18. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.
Jacobs I; Davies AP; Bridges J; Stabile I; Fay T; Lower A; Grudzinskas JG; Oram D
BMJ; 1993 Apr; 306(6884):1030-4. PubMed ID: 8490497
[TBL] [Abstract][Full Text] [Related]
19. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
Plante M; Wong GY; Nisselbaum JS; Almadrones L; Hoskins WJ; Rubin SC
Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
[TBL] [Abstract][Full Text] [Related]
20. [CA 125 in diagnosis and prognosis of epithelial ovarian cancer].
Cohen AD; Piura B; Cohen Y; Shoenfeld Y
Harefuah; 1994 Mar; 126(5):283-5, 303. PubMed ID: 8188111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
